APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
How to identify patients with RA-ILD who can benefit from OFEV
Document ID: PC-CRP-103942
01/08/2023
Author: Boehringer Ingelheim
RELATED CONTENT
PC-CRP-103942
Production Date: August 2023
Production Date: August 2023